The spatial relationship between the binding sites for two cyclic peptides, cyclo(S,S)KYGCRGDWPC (cRGD) and cyclo(S,S)KYGCHarGDWPC (cHarGD), high affinity analogs for the RGD and HLGGAKQAGDV peptide ligands, in integrin ␣ IIb  3 (GPIIb-IIIa) has been characterized. For this purpose, cRGD and cHarGD were labeled with fluorescein isothiocyanate and tetramethylrhodamine 5-isothiocyanate, respectively. Both cyclic peptides were potent inhibitors of fibrinogen binding to ␣ IIb  3 , particularly in the presence of Mn
2؉; IC 50 values for cRGD and cHarGD were 1 and <0.1 nM in the presence of Mn
2؉. Direct binding experiments and fluorescence resonance energy transfer analysis using the purified receptor showed that both peptides interacted simultaneously with distinct sites in ␣ IIb  3 . The distance between these sites was estimated to be 6.1 ؎ 0.5 nm. Although cRGD bound preferentially to one site and cHarGD to the other, the sites were not fully specific, and each cyclic peptide or its linear counterpart could displace the other to some extent. The binding affinity of the cHarGD site was dramatically affected by Mn
2؉. cRGD, but not cHarGD, bound to recombinant  3 -(95-373) in a cation-dependent manner, indicating that the cRGD site is located entirely within this fragment. With intact platelets, binding of c-RGD and cHarGD to ␣ IIb  3 resulted in distinct conformational alterations in the receptor as indicated by the differential exposure of ligand-induced binding site epitopes and also induced the opposite on membrane fluidity as shown by electron paramagnetic resonance analyses using 5-doxylstearic acid as a spin probe. These data support the concept the two peptide ligands bind to distinct sites in ␣ IIb  3 and initiate different functional consequences within the receptor itself and within platelets. ␣ IIb  3 (GPIIb-IIIa) is a member of integrin family of cell adhesion receptors (1-3) and is the most abundant membrane protein on the platelet surface (4). On nonstimulated platelets, ␣ IIb  3 is incapable of binding most of its soluble macromolecular ligands (5), but after exposure of the cells to appropriate agonists, the receptor undergoes a conformational change (6) as a consequence of signal transmission from inside the cell to the extracellular domain of the receptor (inside-out signaling (7, 8)) and becomes competent to interact with several plasma protein ligands, including fibrinogen, fibronectin, and von Willebrand factor (9 -11). Fibrinogen inhibits the binding of other two ligands to ␣ IIb  3 (10 -13), and a common set of monoclonal antibodies (mAbs) 1 to the receptor blocks the interaction of these adhesive ligands with ␣ IIb  3 (9). Two sets of ligand peptides, ␥ chain peptides, which correspond to the sequence at the carboxyl-terminal sequence of the fibrinogen ␥ chain, and RGD(X) peptides, which correspond to sequences present in all three macromolecular ligands, define the recognition specificity of ␣ IIb  3 for its macromolecular ligands (reviewed in Ref. 14). Both peptide sets inhib...